Scarica l'app Stockscreener
27.20
3.82%
-1.08
Pre-mercato:
27.89
0.69
+2.54%
Precedente Chiudi:
$28.28
Aprire:
$28.57
Volume 24 ore:
1.36M
Relative Volume:
1.64
Capitalizzazione di mercato:
$1.63B
Reddito:
$439.00K
Utile/perdita netta:
$-105.64M
Rapporto P/E:
-15.11
EPS:
-1.8
Flusso di cassa netto:
$-60.70M
1 W Prestazione:
+5.22%
1M Prestazione:
+16.19%
6M Prestazione:
-5.19%
1 anno Prestazione:
-44.95%
Intervallo 1D:
$27.02
$29.09
Intervallo di 1 settimana:
$25.18
$29.09
Portata 52W:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
27.20 | 1.55B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Can Janux Therapeutics Inc. stock surprise with earnings upsideForecast Cut & AI Forecast for Swing Trade Picks - newser.com
Real time alert setup for Janux Therapeutics Inc. performanceQuarterly Risk Review & Safe Capital Growth Trade Ideas - newser.com
Is Janux Therapeutics Inc. stock attractive for income investorsJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
Can trapped investors hope for a rebound in Janux Therapeutics Inc.Market Performance Report & Stock Portfolio Risk Control - newser.com
Is Janux Therapeutics Inc. stock poised for growthWeekly Loss Report & High Return Stock Watch Alerts - newser.com
Janux Therapeutics (JANX) Is Up 10.5% After Positive Pipeline Updates and Analyst EPS Revisions – Has the Bull Case Changed? - Sahm
Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Trend analysis for Janux Therapeutics Inc. this weekPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Nasdaq
What drives Janux Therapeutics Inc stock priceEarnings Per Share Trends & Rapid Portfolio Gain - earlytimes.in
Weiss Ratings Reaffirms Sell (D-) Rating for Janux Therapeutics (NASDAQ:JANX) - MarketBeat
Visual trend scoring systems applied to Janux Therapeutics Inc.Market Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans - Sahm
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring the 245% Upside Potential in Biotech - DirectorsTalk Interviews
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will a bounce in Janux Therapeutics Inc. offer an exitMarket Movement Recap & AI Enhanced Trading Signals - newser.com
How geopolitical tensions affect Janux Therapeutics Inc. stock2025 Momentum Check & Risk Controlled Stock Pick Alerts - newser.com
Janux Therapeutics Inc. recovery potential after sell offDollar Strength & Real-Time Volume Surge Alerts - newser.com
Leading vs lagging indicators on Janux Therapeutics Inc. performanceJuly 2025 Outlook & Community Supported Trade Ideas - newser.com
Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Janux Therapeutics(JANX.US) With Buy Rating - 富途牛牛
What earnings revisions data tells us about Janux Therapeutics Inc.Recession Risk & Daily Profit Maximizing Tips - newser.com
Using data tools to time your Janux Therapeutics Inc. exitWeekly Trend Summary & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-10-03 01:15:11 - newser.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $78.31 Average PT from Brokerages - Defense World
Will Q4 Earnings Be a Catalyst for Jash Engineering LimitedDay Trading Setups & Affordable Investment Tips - earlytimes.in
Published on: 2025-09-29 03:27:23 - newser.com
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Janux Therapeutics Inc Azioni (JANX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):